Theodore Karrison to Neoplasm, Residual
This is a "connection" page, showing publications Theodore Karrison has written about Neoplasm, Residual.
Connection Strength
0.139
-
Elotuzumab and Weekly Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Without Transplant Intent: A Phase 2 Measurable Residual Disease-Adapted Study. JAMA Oncol. 2022 09 01; 8(9):1278-1286.
Score: 0.050
-
Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer. 2022 08 01; 128(15):2967-2977.
Score: 0.050
-
Dormancy of mammary carcinoma after mastectomy. J Natl Cancer Inst. 1999 Jan 06; 91(1):80-5.
Score: 0.039